BYSI
BeyondSpring Inc.
Next earnings Aug 11, 2026
Last earnings +4.3% on 2026-05-13
$1.87
▲ +4.47%$1.87▼ -23.67%
over 1Y
L $1.27H $2.45
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.5%
1W+16.9%
1M+10.0%
3M+8.4%
YTD+16.1%
1Y-23.7%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 7 analysts
Buy
Clinical-stage biopharma with no revenue, negative equity and ~$8M cash against ~$20M annual burn — a binary, balance-sheet-stressed bet, not investable.
Revenue $0.00 · FY2025
The balance sheet is the disqualifier. Stockholders' equity is NEGATIVE $32.2M (liabilities/equity -1.55x), total liabilities $49.9M dwarf total assets of $25.9M, and the accumulated deficit is -$408M. Cash is just $7.79M against operating cash burn of -$19.8M/year — less than five months of runway at the current rate, before the cost of a global phase 3 the company says it intends to launch. That sets up near-certain dilution or financing on punitive terms, and the going-concern overhang is real. The headline 'net loss narrowed 91% to -$1.01M' is misleading: operating loss was still -$8.95M (essentially flat YoY), so the bottom-line improvement comes from non-operating/fair-value items, not from the business getting healthier. R&D actually rose 66% to $4.39M.
Is BYSI a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~90d expiry
- Long put 2 @ ~0.32 est
- Short put 1.5 @ ~0.08 est
debit $24max +$26max −$24BE 1.76
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.35M | $1.35M | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$66.2M | -$37.2M | -$15.1M | -$8.75M | -$8.95M |
| Net income | -$64.2M | -$33.3M | -$21.0M | -$11.1M | -$1.01M |
| Diluted EPS | -$1.64 | — | — | — | — |
| Net margin | -4750.5% | -2463.3% | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$68.3M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-1.3%
FCF yield-26.1%
Quality & risk
ROIC (est.)—
Free cash flow-$19.8M
Total debt$0.00
Net cash$7.79M
Altman Z-Score-21.94 distress
Piotroski F-Score2/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K/A Amended 8-K2026-06-29
Amendment adding required exhibits/details to prior 8-K
- 8-K Officer / director change2026-06-04
Officer/director change (5.02) plus Reg FD update; leadership transition disclosed
- 8-K Earnings results2026-05-13
Q1 2026: no revenue, narrowing net loss but thin $7.8M cash vs heavy burn
- 10-Q Quarterly report2026-05-13
Q1 2026: no revenue, narrowing net loss but thin $7.8M cash vs heavy burn
- 8-K Earnings results2026-03-25
FY2025: negative equity -$32M, $7.8M cash vs $20M burn — going-concern risk
- 10-K Annual report2026-03-25
FY2025: negative equity -$32M, $7.8M cash vs $20M burn — going-concern risk
- 8-K Other event2025-12-15
Other-events disclosure (8.01), likely pipeline/regulatory update
- 8-K Material agreement2025-11-21
Entered material definitive agreement (1.01) — likely financing/collaboration
- 8-K Earnings results2025-11-12
Q3 2025: ongoing losses, negative equity, tight liquidity
Recent filings
all on EDGAR ↗8-K/APeriod ending 2026-06-042026-06-29open ↗8-KPeriod ending 2026-06-042026-06-04open ↗4Period ending 2026-03-202026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-13open ↗8-KPeriod ending 2026-05-132026-05-13open ↗4Period ending 2026-04-012026-04-08open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗4Period ending 2026-04-012026-04-03open ↗
Frequently asked
- Is BeyondSpring Inc. (BYSI) a buy?
- BYSI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Clinical-stage biopharma with no revenue, negative equity and ~$8M cash against ~$20M annual burn — a binary, balance-sheet-stressed bet, not investable.
- What is BeyondSpring Inc.'s quality score?
- BYSI scores 59.09768071779245/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001677940, latest 10-Q filed 2026-05-13) · EODHD · Proprietary analysis · as of 6/30/2026, 1:03:58 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 30, 2026, 9:03 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.